OKYO Pharma to Release Dry Eye Trial Data March 22
Ticker: OKYO · Form: 6-K · Filed: Mar 20, 2024 · CIK: 1849296
| Field | Detail |
|---|---|
| Company | Okyo Pharma LTD (OKYO) |
| Form Type | 6-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, biotech, drug-development
TL;DR
OKYO Pharma dropping Phase 2 dry eye data Friday - big news incoming!
AI Summary
OKYO Pharma Ltd announced on March 20, 2024, that it will release new efficacy data from its Phase 2 trial of OK-101 for dry eye disease on March 22, 2024. The company will also host a Key Opinion Leader (KOL) event to discuss the trial results.
Why It Matters
The upcoming data readout from the Phase 2 trial of OK-101 could significantly impact OKYO Pharma's development trajectory and the potential treatment landscape for dry eye disease.
Risk Assessment
Risk Level: medium — The outcome of clinical trial data releases can be highly volatile and significantly impact stock prices.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- OK-101 (drug) — Drug candidate for dry eye disease
FAQ
What specific type of data will be released from the Phase 2 trial of OK-101?
The filing states that new and comprehensive efficacy data will be released.
When will OKYO Pharma release the Phase 2 trial data?
The data will be released on March 22, 2024.
What is the indication for the drug OK-101?
OK-101 is being tested for dry eye disease.
What event will accompany the data release?
OKYO Pharma will host a Key Opinion Leader (KOL) event to discuss the trial results.
What is the filing date of this Form 6-K?
This Form 6-K was filed on March 20, 2024.
Filing Stats: 359 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-03-20 08:07:39
Filing Documents
- form6-k.htm (6-K) — 21KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-010618.txt ( ) — 50KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: March 20, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated March 20, 2024 4